Sequencing Considerations and Planning in EGFR+ NSCLC

Christine Lovly, MD, PhD, and Matthew Lee, MD, explore key considerations for treatment sequencing across the EGFR-mutated non–small cell lung cancer continuum. Lovly explains how frontline choices can influence downstream options, particularly in the context of resistance pathways and CNS involvement. Lee adds that a proactive, longitudinal treatment strategy is critical to optimizing outcomes as more therapies become available.